IP Library Granted Patent US 11,497,752
Granted Patent B2
US 11,497,752 · App. 16/965,822 · Granted Nov 15, 2022

Compounds and uses thereof

Inventors: Neville John Anthony (Northborough, MA); David Simon Millan (Stow, MA); Rishi G. Vaswani (Lexington, MA); Shawn E. R. Schiller (Haverhill, MA)
Assignee: Foghorn Therapeutics Inc.
A61K31/541A61K31/427A61K31/4409A61K31/4425A61K31/4439A61K31/4709A61K31/496A61K31/506A61K31/5377A61K45/06A61P35/04C07D277/46C07D417/04C07D417/10C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,497,752
App. No.
16/965,822
Granted
Nov 15, 2022
Kind
B2
Abstract

The present disclosure features compounds useful for the treatment of BAF complex-related disorders.

Claims (18)

1. A compound having the structure of Formula I:

wherein

B is

optionally substituted C 2 -C 9 heteroaryl, or C 2 -C 9 heterocyclyl;

R is

wherein R 1 is optionally substituted C 1 -C 3 alkyl or optionally substituted C 3 -C 6 cycloalkyl;

each R 3 and R 5 is, independently, selected from the group consisting of H, optionally substituted C 1 -C 6 alkyl, or optionally substituted C 1 -C 6 heteroalkyl;

R 4 is hydrogen, or optionally substituted C 1 -C 6 heteroalkyl; and

R 6 is optionally substituted C 6 -C 10 aryl or optionally substituted C 2 -C 9 heteroaryl

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound has the structure

wherein R 1 is optionally substituted C 1 -C 3 alkyl,

or a pharmaceutically acceptable salt thereof.

3. A compound having the structure of any one of compounds

and pharmaceutically acceptable salts thereof.

4. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

5. The compound of claim 1 , wherein both R 3 and R 5 are H.

6. The compound of claim 1 , wherein R 4 is H,

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2021
From: ANTHONY, NEVILLE JOHN; MILLAN, DAVID SIMON; VASWANI, RISHI G.; SCHILLER, SHAWN E.R.
To: FOGHORN THERAPEUTICS INC.
Reel/Frame 054830/0410 →
Continuity (5)
Provisional Application 62789260 · Jan 7, 2019
Provisional Application 62770431 · Nov 21, 2018
Provisional Application 62653229 · Apr 5, 2018
Provisional Application 62623907 · Jan 30, 2018
Related Publication 20210038611A1 · Feb 11, 2021
Cited By (8)
US 12,383,555 US 12,383,560 US 12,384,776 US 12,473,334 US 12,486,262 US 12,509,453 US 12,606,553 US 12,649,737